
Libby Babu Varghese
Counsel
212-784-6922 lvarghese@sh-law.comFirm News
Author: Libby Babu Varghese
Date: May 15, 2020
Counsel
212-784-6922 lvarghese@sh-law.comIn an effort to foster innovation, the U.S. Patent and Trademark Office (USPTO) recently announced a new COVID-19 Prioritized Examination Pilot Program. To qualify, the claim(s) of an application must cover a product or process related to COVID-19, and the product or process must be subject to an applicable FDA approval for COVID-19 use. The pilot is limited to applicants that qualify for either small or micro entity status, including small businesses and individual inventors.
Patents that are fast-tracked through the program could reach a final decision in as fast as six months. In addition, qualifying applicants will not need to pay the USPTO’s typical prioritized examination fees.
“Independent inventors and small businesses are often the difference-makers when it comes to cutting-edge innovation and the growth of our economy,” Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director of the USPTO said in a press statement. “They are also in most need of assistance as we fight this pandemic. Accelerating examination of COVID-19-related patent applications, without additional fees, will permit such innovators to bring important and possibly life-saving treatments to market more quickly.”
Typically, the USPTO examines new patent applications in the order of their U.S. filing dates. However, the agency has several programs under which eligible patent applications can be advanced out of turn.
The new COVID-19 Prioritized Examination Pilot Program will provide prioritized examination without payment of the additional fees for prioritized examination for certain applications that claim products or processes that are subject to an applicable FDA approval for COVID-19 use. According to the USPTO, such approvals may include, but are not limited to, an Investigational New Drug (IND) application, an Investigational Device Exemption (IDE), a New Drug Application (NDA), a Biologics License Application (BLA), a Premarket Approval (PMA), or an Emergency Use Authorization (EUA).
The goal of prioritized examination is to provide a final disposition within 12 months, on average, from the date the prioritized status has been granted. However, the USPTO believes it can achieve final disposition in six months if applicants provide more timely responses to notices and actions from the USPTO.
Eligibility Requirements As set forth in the USPTO’s Federal Register Notice, patent applicants seeking to take advantage of the pilot program must satisfy several eligibility requirements. The request for prioritized examination under the pilot program must be made:
The pilot program is reserved for the above nonprovisional applications. Accordingly, any application that claims the benefit of the filing date of two or more prior-filed nonprovisional U.S. applications or international applications designating the United States under 35 U.S.C. 120, 121, or 365(c) is not eligible for participation under the pilot program.
The COVID-19 Prioritized Examination Pilot Program will accept requests for prioritized examination until the USPTO has accepted a total of 500 requests. According to the USPTO, it may extend the pilot program (with or without modifications) or terminate it depending on the “workload and resources needed to administer the program, feedback from the public, and the effectiveness of the program.”
If you have any questions or if you would like to discuss the matter further, please contact me, Libby Varghese, or the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Scarinci Hollenbeck Partner Nathanya G. Simon named by ROI-NJ to the “ROI Influencers: Women in Business” list for fourth consecutive year Scarinci Hollenbeck Partner Nathanya G. Simon has been named by ROI-NJ to the “ROI Influencers: Women in Business” list for 2025. After four decades of practice, Nathanya’s pioneering influence in the field of special […]
Author: Scarinci Hollenbeck, LLC
Congratulations Angela Turiano on appointment as Director of Legislative Affairs for SHRM Princeton April 17, 2025 – Little Falls, NJ – Scarinci & Hollenbeck, LLC congratulates Partner Angela Turiano on her appointment as Director of Legislative Affairs for SHRM Princeton. Along with serving as a member of SHRM Princeton’s leadership team, Angela will monitor pending legislative, regulatory, […]
Author: Scarinci Hollenbeck, LLC
Congratulations Brittany P. Tarabour for Nomination as Three-Year Trustee of the Monmouth Bar Association Red Bank, NJ – April 9, 2025 – Scarinci & Hollenbeck, LLC proudly congratulates Brittany P. Tarabour on her nomination by the Monmouth Bar Association to serve as a Three-Year Trustee. Founded in 1908, the Monmouth Bar Association is dedicated to […]
Author: Scarinci Hollenbeck, LLC
Scarinci Hollenbeck Partner Ron Bienstock Featured on Bloomberg Law Podcast to Discuss Dua Lipa Copyright Infringement Lawsuits Little Falls, NJ – April 8, 2025 – Scarinci & Hollenbeck, LLC Partner and Chair of the firm’s Intellectual Property and Entertainment & Media departments Ronald S. Bienstock was recently featured on the Bloomberg Law podcast to discuss […]
Author: Scarinci Hollenbeck, LLC
Scarinci Hollenbeck Attorneys From Little Falls and Red Bank Named to 2025 New Jersey Super Lawyers List Little Falls, NJ – April 2, 2025 – Scarinci & Hollenbeck, LLC attorneys from both NJ offices were named to the 2025 New Jersey Super Lawyers and Rising Stars list. Each attorney was chosen in recognition of their […]
Author: Scarinci Hollenbeck, LLC
On Thursday, April 3, 2025, Partner Angela Turiano will make her fifth appearance as a mock arbitrator for the Securities Arbitration Clinic at the prestigious Fordham School of Law. Angela will draw on her years of experience to provide feedback to these future lawyers after making opening presentations and closing arguments, with the goal of […]
Author: Scarinci Hollenbeck, LLC
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!